Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 8/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 6/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7145298 | 0.91 | BACE1 (0.42) | SCN2ANPY5RHPGDSCNR1CNR2 | |
| SCHEMBL7138233 | 0.86 | SCN2A (0.55) | SCN2ANPY5RADRA2CHPGDSCNR1 | |
| SCHEMBL8189930 | 0.84 | SCN2A (0.50) | SCN2ANPY5RHPGDSCNR1CNR2 | |
| SCHEMBL7145535 | 0.83 | SCN2A (0.52) | SCN2ANPY5RADRA2CHPGDSCNR1 | |
| SCHEMBL8119297 | 0.82 | SCN2A (0.51) | SCN2ANPY5RHPGDSCNR1CNR2 | |
| SCHEMBL7145532 | 0.82 | SCN2A (0.53) | SCN2ANPY5RHPGDSCNR1CNR2 | |
| SCHEMBL7142374 | 0.81 | SCN2A (0.58) | SCN2ANPY5RHPGDSCNR1CNR2 | |
| SCHEMBL8189931 | 0.81 | SCN2A (0.50) | SCN2ANPY5RADRA2CHPGDSCNR1 | |
| SCHEMBL7187293 | 0.81 | BACE1 (0.44) | SCN2ANPY5RHPGDSCNR1CNR2 | |
| SCHEMBL7140600 | 0.81 | SCN2A (0.52) | SCN2ANPY5RADRA2CHPGDSCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6515133-B1 | Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. | NEUROGEN CORPORATION | 2003-02-04 | — | — | US | claimed |
| US-6515133-B1 | Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. | NEUROGEN CORPORATION | 2003-02-04 | — | — | US | disclosed |
| US-6121260-A | Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives | NEUROGEN CORPORATION (US) | 2000-09-19 | — | — | US | disclosed |
| EP-0996443-A1 | CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999001128-A1 | CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1999-01-14 | — | — | WO | disclosed |